Merck & Co., Inc. stock (US58933Y1055): Keytruda momentum and fresh earnings keep big pharma in focus

Merck & Co., Inc. remains in the spotlight after its latest quarterly update showed strong growth for cancer drug Keytruda and higher full?year guidance, while big shareholders adjust their positions and analysts refine their price targets.

Merck & Co., Inc. has attracted renewed investor attention after its latest quarterly report highlighted robust demand for flagship cancer therapy Keytruda and prompted an increase in full?year guidance, according to Ad-hoc-news.de as of 05/15/2026. The company’s first-quarter 2026 sales reached about 16.29 billion USD, beating consensus estimates of 15.85 billion USD, while adjusted earnings also came in above expectations, as reported by Moomoo as of 05/10/2026.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals and animal health
• Headquarters/country: Rahway, New Jersey, United States
• Core markets: Oncology, vaccines, hospital acute care and animal health
• Key revenue drivers: Keytruda, Gardasil/Gardasil 9, animal health portfolio
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. is one of the largest global pharmaceutical groups, focusing on prescription medicines, vaccines and animal health products. The company generates the majority of its revenue from human pharmaceuticals, particularly oncology therapies such as Keytruda and vaccines like Gardasil, according to the business breakdown shown by MarketScreener as of 11/14/2025. Beyond patented drugs, Merck also has a growing animal health segment that sells vaccines and treatments for livestock and companion animals.

The group’s business model relies on high research and development spending to sustain a pipeline of new medicines and lifecycle extensions for existing brands. In addition to Keytruda and Gardasil, Merck markets treatments across cardiometabolic, immunology and infectious disease indications, typically selling through hospital systems, specialty clinics and vaccination programs. This mix gives the company exposure to both chronic and acute care markets while providing diversification across therapeutic areas.

Merck operates globally but has a particularly strong presence in the United States, Europe and key emerging markets. US sales remain a core profit driver given higher price levels and broad insurance coverage for oncology and vaccine products. The company also increasingly partners with biotech firms to access innovative assets, often signing collaboration and licensing agreements that combine Merck’s commercial scale with external research capabilities, as highlighted in several partnership announcements summarized by Ad-hoc-news.de as of 05/15/2026.

Main revenue and product drivers for Merck & Co., Inc.

Keytruda remains the clear centerpiece of Merck’s portfolio. The immune checkpoint inhibitor continues to post double-digit sales growth thanks to expanding indications across lung, melanoma, head and neck, and other cancers. In the most recent first-quarter 2026 report, management pointed to Keytruda as the primary engine behind overall pharmaceutical revenue growth and a key factor in raising full?year guidance, according to Moomoo as of 05/10/2026. The drug’s broad label and ongoing clinical trials suggest it may continue to support Merck’s top line even as some older products face generic competition.

Vaccines represent another important pillar, led by human papillomavirus vaccine Gardasil and Gardasil 9. Demand for these products has benefited from increased public health focus on cancer prevention and expanded vaccination programs in multiple countries. Recent commentary around Merck noted that Gardasil volumes remain robust, though investors are following upcoming litigation and safety-related proceedings closely, including a Gardasil vaccine safety trial expected in late July, as mentioned by Robinhood as of 05/12/2026. While such cases introduce headline risk, Gardasil continues to be a meaningful source of revenue.

Beyond these two franchises, Merck’s hospital acute care portfolio and animal health division add diversification. Animal health sales stem from products targeting both production animals and pets, giving Merck exposure to long?term trends in protein consumption and pet care spending. MarketScreener data show that human pharmaceuticals accounted for more than 50 billion USD in annual sales in recent years, with animal health contributing over 6 billion USD for the latest reported full?year period, according to MarketScreener as of 11/14/2025. This combination positions Merck as a diversified healthcare group rather than a single?product story, even if Keytruda remains dominant.

Recent earnings: Q1 2026 beat and guidance implications

In first-quarter 2026, Merck posted sales of approximately 16.29 billion USD, beating analyst expectations of 15.85 billion USD and marking another period of solid operational momentum, according to Moomoo as of 05/10/2026. The company recorded a net loss of about 4.24 billion USD for the quarter, largely driven by acquisition?related charges, as summarized by Robinhood as of 05/12/2026. Adjusted earnings per share still came in ahead of consensus, demonstrating the underlying profitability of the core business.

Management also used the earnings release to refine full?year 2026 guidance, citing stronger?than?expected performance of Keytruda and continued uptake of certain vaccines. The update pointed to mid?single?digit to high?single?digit percentage revenue growth in constant currency, depending on underlying assumptions, according to commentary summarized by Ad-hoc-news.de as of 05/15/2026. While exact ranges may change as the year progresses, the guidance underscores Merck’s confidence in sustained demand across its key franchises despite patent expirations in other parts of the portfolio.

For US investors, the earnings beat and guidance update raise questions about valuation, especially given Merck’s large market capitalization and already significant expectations embedded in Keytruda. The combination of strong top?line growth, acquisition?related charges and ongoing litigation costs means that reported net income can fluctuate notably from quarter to quarter. Investors therefore tend to focus on adjusted metrics, cash flow generation and pipeline progress when assessing the sustainability of the current growth profile.

Institutional flows and analyst sentiment

Recent disclosures also show that some institutional investors have been actively adjusting their Merck positions. Antipodes Partners, for example, reduced its stake in the company by about 5.7% in the fourth quarter, selling roughly 95,741 shares while still holding around 1.58 million shares valued at approximately 165.9 million USD at the time of filing, according to MarketBeat as of 05/16/2026. In parallel, other investors such as Convergence Investment Partners LLC disclosed new or increased positions in Merck shares, as reported by MarketBeat as of 05/16/2026.

Analyst sentiment toward Merck remains broadly constructive, with MarketBeat data pointing to an overall Moderate Buy consensus rating and an average price target of around 128.18 USD, according to MarketBeat as of 05/16/2026. However, there are nuances within this picture. Citigroup recently assigned a neutral rating, reflecting a more cautious stance on upside potential, while Wells Fargo trimmed its price objective from 150 USD to 145 USD but maintained an overweight view in a research note published on May 1, 2026, as cited by MarketBeat as of 05/16/2026.

Royal Bank of Canada reiterated an outperform rating and a 142 USD price target in a late?March 2026 report, underscoring confidence in Merck’s oncology growth and pipeline depth, according to details summarized by MarketBeat as of 05/16/2026. Together, these views suggest that professional forecasters see upside potential but also recognize execution risks tied to patent cliffs, competition in oncology and regulatory developments. Retail investors may interpret the range of targets and ratings as a signal that expectations are high but not uniform across the analyst community.

Dividend profile and shareholder returns

Beyond growth prospects, Merck is also followed closely for its dividend profile. According to data from Zacks, the company currently pays an annualized dividend of about 3.40 USD per share, corresponding to a yield near 3.0% at a share price of 79.10 USD, based on market levels observed on June 27, 2025, as reported by Zacks as of 06/27/2025. Zacks also notes that Merck has increased its dividend six times over the past five years, signaling a commitment to returning cash to shareholders while funding its research pipeline.

For income?oriented US investors, this dividend track record can be a meaningful consideration, particularly in comparison with other large pharmaceutical peers that also offer yields in the low?to?mid single?digit range. The sustainability of the payout depends on Merck’s ability to maintain strong cash flows from its key franchises and manage spending on research, acquisitions and litigation. While buyback activity does not dominate the story currently, the dividend provides an additional layer of potential total return on top of any share price movement linked to fundamental performance.

As always, dividend investors need to account for the possibility that large litigation settlements, acquisitions or unexpected pipeline setbacks could influence capital allocation plans. However, Merck’s diversified revenue base and long history as a blue?chip healthcare company may provide some comfort to market participants who prioritize stability alongside growth potential.

Why Merck & Co., Inc. matters for US investors

Merck’s relevance for US investors extends beyond its own share price. As a major component of leading healthcare and broad?market indices, Merck’s performance can influence sector exchange?traded funds and retirement portfolios that track these benchmarks. Movements in MRK shares often correlate with broader sentiment toward big pharma and biotech, particularly around regulatory or reimbursement developments that affect drug pricing in the United States, according to sector commentary frequently cited by Ad-hoc-news.de as of 05/15/2026.

For investors focused on the US healthcare system, Merck’s oncology and vaccine franchises offer exposure to long?term demographic and medical trends, including aging populations and the growing importance of immuno?oncology therapies. The company’s deep involvement in public and private insurance markets, hospital systems and vaccination campaigns means that policy changes or reimbursement shifts can have direct financial consequences. As a result, MRK is often seen as a bellwether for how large, diversified drug makers are navigating pricing pressures and the transition toward value?based care models in the United States.

From a portfolio construction perspective, Merck may serve as a defensive element in equity allocations given the relatively resilient demand for essential medicines and vaccines. However, the stock also carries specific risks related to patent cliffs, regulatory scrutiny and high research spending, which investors must weigh against perceived stability. The interplay between these defensive and growth characteristics helps explain why Merck remains a core holding for many US asset managers and appears frequently in discussions of long?term healthcare themes.

Conclusion

Merck & Co., Inc. remains a central player in global pharmaceuticals, with Keytruda and Gardasil driving strong revenue momentum and supporting an improved outlook for 2026. The latest quarterly results show that underlying demand for core products is robust, even as acquisition?related charges weigh on reported net income in the near term. Analyst sentiment is broadly positive but nuanced, and recent institutional trading activity underscores that professional investors are continuously reassessing risk?reward dynamics.

For US market participants, Merck offers exposure to key oncology and vaccine trends, a sizeable dividend and a balance of defensive and growth characteristics. At the same time, concentration in a few blockbuster products, ongoing litigation and policy risks around drug pricing remain important factors to monitor. How the company manages its pipeline, capital allocation and regulatory environment over the next several years will likely shape whether the current growth trajectory can be maintained without undue volatility in shareholder returns.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.